New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
08:17 EDTMSTXMast Therapeutics agrees to acquire Aires Pharmaceuticals
Mast Therapeutics announced that it has entered into a definitive agreement to acquire Aires Pharmaceuticals, a clinical stage pharmaceutical company developing therapies to treat pulmonary vascular disorders such as pulmonary arterial hypertension and pulmonary hypertension due to heart failure. Aires' lead product, AIR001, is an intermittently nebulized formulation of nitrite and has orphan drug status with the FDA and the EMA for the treatment of pulmonary arterial hypertension. Under the terms of the all-stock transaction, Aires would become a wholly-owned subsidiary of Mast Therapeutics. The acquisition is expected to close in February 2014, subject to customary closing conditions.
News For MSTX From The Last 14 Days
Check below for free stories on MSTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
07:26 EDTMSTXPiper Jaffray to hold a conference
Subscribe for More Information
September 8, 2014
08:01 EDTMSTXMast Therapeutics announces positive results from Phase 2 study of AIR001
Mast Therapeutics reported top-line results from a Phase 2 study of AIR001 inhalation solution for the treatment of pulmonary arterial hypertension. Mast obtained the rights to the AIR001 program through its acquisition of privately-held Aires Pharmaceuticals earlier this year. In the primary efficacy analysis of the Phase 2 study, all doses showed improvement in median pulmonary vascular resistance. In the secondary efficacy analysis, all doses showed improvements in the median distances obtained in the 6-minute walk test, including clinically-meaningful improvements at the highest dose level. Additionally, AIR001 was well-tolerated, with no treatment related serious adverse events. In particular, methemoglobin levels remained normal, which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use